• News
  • Publications
  • Videos
  • Events
  • About
  • Contact

Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening

November 6, 2020

Abstract Patients with well-differentiated thyroid cancer, especially papillary thyroid cancer (PTC), are treated with surgical resection of the thyroid gland. This is followed by post-operative radioactive iodine (I 131 ), resulting in total thyroid ablation. Unfortunately, about 15-33% of PTC patients are unable to take up I 131 , […]

View Original Source at Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening

Weekly Digest

Sign up to receive
weekly updates!

    No Spum Guarantee

    Cancer Types

    • Bladder Cancer Research (2)
    • Bowel Cancer Research (3)
    • Brain Cancer Research (7)
    • Breast cancer (6)
    • cervical cancer (1)
    • colon (1)
    • Colon cancer (14)
    • colorectal cancer (6)
    • Drug development (12)
    • Endometrial cancer (2)
    • Esophageal cancer (3)
    • Gastric cancer (5)
    • Hans Clevers (1)
    • Head and neck cancer (4)
    • Immunotherapy (0)
    • Intestinal cancer (8)
    • intestinal organoids (1)
    • Kidney cancer (3)
    • Leukemia (1)
    • Liver cancer (11)
    • Lung cancer (4)
    • melanoma (1)
    • metastatic cancer (1)
    • Organoid (143)
    • Ovarian cancer (8)
    • Pancreatic cancer (19)
    • Peritoneal cancer (1)
    • Personalized medicine (5)
    • Prostate cancer (7)
    • Rectal cancer (1)
    • solid tumor (1)
    • stem cells (1)

    ORG
    1-617-547-9443

    Monday-Friday: 8 am - 8 pm
    Saturday: 8 am - 4:30 pm

    • News
    • Publications
    • Videos
    • Events
    • About Us
    • Contact Us
    • Privacy
    • Terms of Use

    © COPYRIGHT 2023 Organoid Research Group. ALL RIGHTS RESERVED.